Revealing the structural basis of action of hERG potassium channel activators and blockers

Journal of Physiology

Volumn 588, Issue 17, 2010, Pages 3157-3167

  Perry, Matthew ^a   Sanguinetti, Michael ^a   Mitcheson, John ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; A 935142; ALMOKALANT; AMIODARONE; AZIMILIDE; CISAPRIDE; CLOFILIUM; FLUVOXAMINE; IBUTILIDE; ICA 105574; NIFEKALANT; NS 1643; PD 118057; PD 307243; PIPERANOMETOZINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; RPR 260243; TERFENADINE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; 4 [3 (6 METHOXY 4 QUINOLINYL) 3 OXOPROPYL] 1 [3 (2,3,5 TRIFLUOROPHENYL) 2 PROPYNYL] 3 PIPERIDINECARBOXYLIC ACID; GLYCINE; ISOLEUCINE; KB 130015; PD 306243; PHENYLALANINE; POTASSIUM CHANNEL STIMULATING AGENT; PROLINE; TYROSINE;

ACTION POTENTIAL; ALPHA CHAIN; BINDING AFFINITY; BINDING SITE; CHANNEL GATING; CONFERENCE PAPER; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TORSADE DES POINTES; ALPHA HELIX; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONFORMATION; DEPOLARIZATION; DRUG POTENCY; DRUG SENSITIVITY; ERG GENE; FACILITATION; GENE; GENE MUTATION; MEMBRANE POTENTIAL; MUTATIONAL ANALYSIS; PATHOPHYSIOLOGY; PROTEIN MOTIF; QT INTERVAL; REPOLARIZATION;

ANIMALS; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING;

EID: 77956277962     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2010.194670     Document Type: Conference Paper

References (70)

1. Carmeliet E. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ Res 1993, 73:857-868.
2. Casis O, Olesen SP, Sanguinetti MC. Mechanism of action of a novel human ether-a-go-go-related gene channel activator. Mol Pharmacol 2006, 69:658-665.
3. Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci U S A 2002, 99:12461-12466.
4. Fan JS, Jiang M, Dun W, Mcdonald TV, Tseng GC. Effects of outer mouth mutations on hERG channel function: a comparison with similar mutations in the Shaker channel. Biophys J 1999, 76:3128-3140.
5. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004, 279:10120-10127.
6. Ficker E, Dennis A, Kuryshev Y, Wible BA, Brown AM. HERG channel trafficking. Novartis Found Symp 2005, 266:57-69. discussion 70-54, 95-59
7. Ficker E, Jarolimek W, Brown AM. Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K+ channels. Mol Pharmacol 2001, 60:1343-1348.
8. Ficker E, Jarolimek W, Kiehn J, Baumann A, Brown AM. Molecular determinants of dofetilide block of HERG K+ channels. Circ Res 1998, 82:386-395.
9. Gerlach AC, Stoehr SJ, Castle NA. Pharmacological removal of human ether-a-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol 2010, 77:58-68.
10. Gessner G, Macianskiene R, Starkus JG, Schonherr R, Heinemann SH. The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism. Eur J Pharmacol 2010, 632:52-59.
11. Gordon E, Lozinskaya IM, Lin Z, Semus SF, Blaney FE, Willette RN, Xu X. 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels. Mol Pharmacol 2008, 73:639-651.
12. Grunnet M, Hansen RS, Olesen SP. hERG1 channel activators: a new anti-arrhythmic principle. Prog Biophys Mol Biol 2008, 98:347-362.
13. Hancox JC, Mcpate MJ, El Harchi A, Zhang YH. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Ther 2008, 119:118-132.
14. Hansen RS, Diness TG, Christ T, Wettwer E, Ravens U, Olesen SP, Grunnet M. Biophysical characterization of the new human ether-a-go-go-related gene channel opener NS3623 [N-(4-bromo-2-(1H-tetrazol-5-yl)-phenyl)-N′-(3′-trifluoromethylphenyl)urea]. Mol Pharmacol 2006, 70:1319-1329.
15. Hardman RM, Stansfeld PJ, Dalibalta S, Sutcliffe MJ, Mitcheson JS. Activation gating of hERG potassium channels: S6 glycines are not required as gating hinges. J Biol Chem 2007, 282:31972-31981.
16. Herzberg IM, Trudeau MC, Robertson GA. Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. J Physiol 1998, 511:3-14.
17. Hosaka Y, Iwata M, Kamiya N, Yamada M, Kinoshita K, Fukunishi Y, Tsujimae K, Hibino H, Aizawa Y, Inanobe A, Nakamura H, Kurachi Y. Mutational analysis of block and facilitation of HERG current by a class III anti-arrhythmic agent, nifekalant. Channels (Austin) 2007, 1:198-208.
18. Imai YN, Ryu S, Oiki S. Docking model of drug binding to the human ether-a-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. J Med Chem 2009, 52:1630-1638.
19. Jiang M, Dun W, Fan JS, Tseng GN. Use-dependent 'agonist' effect of azimilide on the HERG channel. J Pharmacol Exp Ther 1999, 291:1324-1336.
20. Jiang M, Zhang M, Maslennikov IV, Liu J, Wu DM, Korolkova YV, Arseniev AS, Grishin EV, Tseng GN. Dynamic conformational changes of extracellular S5-P linkers in the hERG channel. J Physiol 2005, 569:75-89.
21. Jiang YX, Lee A, Chen JY, Cadene M, Chait BT, Mackinnon R. The open pore conformation of potassium channels. Nature 2002, 417:523-526.
22. Ju P, Pages G, Riek RP, Chen PC, Torres AM, Bansal PS, Kuyucak S, Kuchel PW, Vandenberg JI. The pore domain outer helix contributes to both activation and inactivation of the HERG K+ channel. J Biol Chem 2009, 284:1000-1008.
23. Kamiya K, Mitcheson JS, Yasui K, Kodama I, Sanguinetti MC. Open channel block of HERG K+ channels by vesnarinone. Mol Pharmacol 2001, 60:244-253.
24. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC. Molecular determinants of HERG channel block. Mol Pharmacol 2006, 69:1709-1716.
25. Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008, 108:301-307.
26. Kang J, Chen Xl, Wang H, Ji J, Cheng H, Incardona J, Reynolds W, Viviani F, Tabart M, Rampe D. Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol 2005, 67:827-836.
27. Labro AJ, Raes AL, Bellens I, Ottschytsch N, Snyders DJ. Gating of shaker-type channels requires the flexibility of S6 caused by prolines. J Biol Chem 2003, 278:50724-50731.
28. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 2000, 57:367-374.
29. Liu J, Zhang M, Jiang M, Tseng GN. Structural and functional role of the extracellular S5-P linker in the HERG potassium channel. J Gen Physiol 2002, 120:723-737.
30. Liu J, Zhang M, Jiang M, Tseng GN. Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes. J Gen Physiol 2003, 121:599-614.
31. Long SB, Campbell EB, Mackinnon R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005, 309:897-903.
32. McPate MJ, Duncan RS, Hancox JC, Witchel HJ. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol 2008, 155:957-966.
33. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003, 139:887-898.
34. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC. hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun 2006, 351:273-280.
35. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000a, 97:12329-12333.
36. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000b, 115:229-240.
37. Myokai T, Ryu S, Shimizu H, Oiki S. Topological mapping of the asymmetric drug binding to the human ether-a-go-go-related gene product (HERG) potassium channel by use of tandem dimers. Mol Pharmacol 2008, 73:1643-1651.
38. Perrin MJ, Kuchel PW, Campbell TJ, Vandenberg JI. Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-a-go-go-related gene channels. Mol Pharmacol 2008, 74:1443-1452.
39. Perry M, De Groot MJ, Helliwell R, Leishman D, Tristani-Firouzi M, Sanguinetti MC, Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol Pharmacol 2004, 66:240-249.
40. Perry M, Sachse FB, Abbruzzese J, Sanguinetti MC. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K+ conductance. Proc Natl Acad Sci U S A 2009, 106:20075-20080.
41. Perry M, Sachse FB, Sanguinetti MC. Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. Proc Natl Acad Sci U S A 2007, 104:13827-13832.
42. Perry M, Stansfeld PJ, Leaney J, Wood C, De Groot MJ, Leishman D, Sutcliffe MJ, Mitcheson JS. Drug binding interactions in the inner cavity of HERG channels: molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol Pharmacol 2006, 69:509-519.
43. Piper DR, Varghese A, Sanguinetti MC, Tristani-Firouzi M. Gating currents associated with intramembrane charge displacement in HERG potassium channels. Proc Natl Acad Sci U S A 2003, 100:10534-10539.
44. Piper DR, Hinz WA, Tallurri CK, Sanguinetti MC, Tristani-Firouzi M. Regional specificity of hERG channel activation and inactivation gating. J Biol Chem 2005, 280:7206-7217.
45. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 2006, 149:481-489.
46. Recanatini M, Poluzzi E, Masetti M, Cavalli A, De Ponti F. QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development. Med Res Rev 2005, 25:133-166.
47. Redfern WS, Carlsson L, Davis AS, Lynch WG, Mackenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58:32-45.
48. Ridley JM, Dooley PC, Milnes JT, Witchel HJ, Hancox JC. Lidoflazine is a high affinity blocker of the HERG K+ channel. J Mol Cell Cardiol 2004, 36:701-705.
49. Roden DM. Mechanisms and management of proarrhythmia. Am J Cardiol 1998, 82:49I-57I.
50. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003, 63:1051-1058.
51. Sanchez-Chapula JA, Navarro-Polanco RA, Culberson C, Chen J, Sanguinetti MC. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J Biol Chem 2002, 277:23587-23595.
52. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995, 81:299-307.
53. Schonherr R, Heinemann SH. Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. J Physiol 1996, 493:635-642.
54. Smith PL, Baukrowitz T, Yellen G. The inward rectification mechanism of the HERG cardiac potassium channel. Nature 1996, 379:833-836.
55. Smith PL, Yellen G. Fast and slow voltage sensor movements in HERG potassium channels. J Gen Physiol 2002, 119:275-293.
56. Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides. Circ Res 1996a, 78:499-503.
57. Spector PS, Curran ME, Zou A, Keating MT, Sanguinetti MC. Fast inactivation causes rectification of the IKr channel. J Gen Physiol 1996b, 107:611-619.
58. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes: KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102:1178-1185.
59. Stansfeld PJ, Grottesi A, Sands ZA, Sansom MS, Gedeck P, Gosling M, Cox B, Stanfield PR, Mitcheson JS, Sutcliffe MJ. Insight into the mechanism of inactivation and pH sensitivity in potassium channels from molecular dynamics simulations. Biochemistry 2008, 47:7414-7422.
60. Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M, Hering S. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 2007, 151:1368-1376.
61. Subbiah RN, Clarke CE, Smith DJ, Zhao J, Campbell TJ, Vandenberg JI. Molecular basis of slow activation of the human ether-á-go-go related gene potassium channel. J Physiol 2004, 558:417-431.
62. Subbiah RN, Kondo M, Campbell TJ, Vandenberg JI. Tryptophan scanning mutagenesis of the HERG K+ channel: the S4 domain is loosely packed and likely to be lipid exposed. J Physiol 2005, 569:367-379.
63. Su Z, Limberis J, Souers A, Kym P, Mikhail A, Houseman K, Diaz G, Liu X, Martin RL, Cox BF, Gintant GA. Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol 2009, 77:1383-1390.
64. Swartz KJ. Towards a structural view of gating in potassium channels. Nat Rev Neurosci 2004, 5:905-916.
65. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995, 269:92-95.
66. Webster SM, Del Camino D, Dekker JP, Yellen G. Intracellular gate opening in Shaker K+ channels defined by high-affinity metal bridges. Nature 2004, 428:864-868.
67. Xu X, Recanatini M, Roberti M, Tseng GN. Probing the binding sites and mechanisms of action of two human ether-a-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243). Mol Pharmacol 2008, 73:1709-1721.
68. Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J Pharmacol Exp Ther 2006, 319:957-962.
69. Zhang M, Liu J, Tseng GN. Gating charges in the activation and inactivation processes of the HERG channel. J Gen Physiol 2004, 124:703-718.
70. Zhou J, Augelli-Szafran CE, Bradley JA, Chen X, Koci BJ, Volberg WA, Sun Z, Cordes JS. Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol 2005, 68:876-884.